Latest ACE inhibitor Stories

AbbVie presents results of Phase 2b studies NORTH CHICAGO, Ill., May 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease (CKD) and type 2 diabetes. SONAR is a large, multinational,...

EXTON, Pa., March 14, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that nephrologists believe that diabetic nephropathy is the renal condition with the highest unmet need for treatment, followed closely by acute kidney injury and polycystic kidney disease, according to TreatmentTrends: Diabetic Nephropathy (U.S.), a study of 105 U.S. physicians (52 nephrologists, 26...

Absolute risk still low, but doctors and patients should be vigilant Patients who take a triple combination of blood pressure drugs and common painkillers are at an increased risk of serious kidney problems, especially at the start of treatment, finds a study published on bmj.com today. Although the absolute risk for individuals is low, it is still something doctors and patients should be aware of, say the researchers. Acute kidney injury (also known as kidney failure) is a major...

A novel study from Karolinska Institutet in Sweden suggests that commonly used drugs to treat heart failure and high blood pressure may have a wider range of application than earlier known, and also can be used against so called HFPEF -- a type of heart failure that until now has been impossible to treat. The study, which is published in the scientific journal JAMA, shows that the mortality rate in a group of HFPEF patients who used these medications decreased. Heart failure affects 3 per...

An analysis of two heart failure therapies finds differing outcomes regarding improvement in survival, according to two studies appearing in the November 28 issue of JAMA. In one study, Adrian F. Hernandez, M.D., M.H.S., of the Duke Clinical Research Institute, Durham, N.C., and colleagues examined the clinical effectiveness of aldosterone antagonist therapy and associations with long-term outcomes of older patients discharged from a hospitalization for heart failure. "Aldosterone...

DEERFIELD, Ill., Sept. 5, 2012 /PRNewswire/ -- Results of a 10-week, phase 3 study published online in the American Journal of Medicine found the clinic systolic blood pressure (SBP) reductions of a fixed-dose combination of azilsartan medoxomil and chlorthalidone were significantly greater at six and ten weeks than those of azilsartan medoxomil co-administered with hydrochlorothiazide. Data also showed that more patients achieved their target blood pressure levels at the end...

Taxpayers could save millions of dollars if hospitals and provincial governments harmonized their prescription drug plans, new research suggests. Hospitals in Canada manage their formularies – the list of generic and brand-name drugs they dispense – independently. Yet many patients are discharged on medications they will have to purchase through publicly funded drug benefits programs. Dr. Chaim Bell, a physician and researcher at St. Michael's Hospital and scientist at the Institute...

DEERFIELD, Ill., June 19, 2012 /PRNewswire/ -- Results of a 12-week, head-to-head, phase 3 study published online in the American Heart Association journal Hypertension found systolic blood pressure (SBP) reductions of a fixed-dose combination of azilsartan medoxomil and chlorthalidone 40/25 mg were statistically superior to those of the fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide 40/25 mg. This fixed-dose combination (azilsartan medoxomil and...

Image Credit: Photos.com --- Connie K. Ho for RedOrbit.com New findings from the Grady Trauma Project report that traumatized people who take a type of blood pressure medication often have less intense post-traumatic stress disorder (PTSD) symptoms. The results show that angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) could be used to help treat patients with PSTD. The study was conducted with over 5,000 low-income Atlanta residents who were...

Results of study using animal model among the presentations at the meeting Experimental Biology 2012 Heart failure is the most common cause of death throughout the world, typically the result of chronic high blood pressure, also known as hypertension. As a result, research efforts have focused on an array of approaches aimed at preventing and treating high blood pressure. Recently, Japanese researchers examined the utility of an anti-hypertensive drug, moxonidine, which acts on the...